» Articles » PMID: 1466470

Metabolism of Ketamine Stereoisomers by Human Liver Microsomes

Overview
Journal Anesthesiology
Specialty Anesthesiology
Date 1992 Dec 1
PMID 1466470
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Ketamine is used clinically as a racemic mixture of optical isomers that differ in their analgesic properties and psychomimetic effects. Administered individually, or together as the racemate, ketamine enantiomers differ in their hepatic clearance and duration of anesthetic effect. S(+) ketamine exhibits a greater clearance and faster anesthetic recovery compared to the racemate and a greater clearance compared to R(-) ketamine. Ketamine undergoes extensive hepatic metabolism, primarily via N-demethylation to norketamine, yet little is known about the human metabolism of ketamine enantiomers. The purpose of this investigation therefore was to characterize ketamine racemate and enantiomer metabolism by human liver and to test the hypothesis that differences in hepatic ketamine enantiomer metabolism can account for observed differences in ketamine enantiomer pharmacokinetics. Ketamine N-demethylation by microsomes from three human livers was measured by gas chromatography-mass spectrometry. At ketamine concentrations typically achieved during anesthesia (5 microM), the rate of S(+) ketamine demethylation was 20% greater than that of R(-) ketamine and 10% greater than that of the racemate (P < .05). At all ketamine concentrations, the rate of racemate demethylation was less than the sum of the rates for the individual enantiomers, reflecting a metabolic enantiomeric interactin whereby one ketamine enantiomer inhibits the metabolism of the other enantiomer. N-demethylation of racemic ketamine and each enantiomer was catalyzed by two apparent enzymes, a high affinity-low capacity enzyme (Km1 30-50 microM, Vmax1 2-6 nmoles.min-1 x nmole-1) and a low affinity-high capacity enzyme (Km2 600-800 microM, Vmax2 9-15 nmoles.min-1 x nmole-1).(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Beyond NMDA Receptors: A Narrative Review of Ketamine's Rapid and Multifaceted Mechanisms in Depression Treatment.

Antos Z, Zukow X, Bursztynowicz L, Jakubow P Int J Mol Sci. 2025; 25(24.

PMID: 39769420 PMC: 11728282. DOI: 10.3390/ijms252413658.


Antidepressants enter cells, organelles, and membranes.

Blumenfeld Z, Bera K, Castren E, Lester H Neuropsychopharmacology. 2023; 49(1):246-261.

PMID: 37783840 PMC: 10700606. DOI: 10.1038/s41386-023-01725-x.


Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression.

Borsellino P, Krider R, Chea D, Grinnell R, Vida T Pharmaceuticals (Basel). 2023; 16(5).

PMID: 37242525 PMC: 10221455. DOI: 10.3390/ph16050742.


Enantioselective CE-MS analysis of ketamine metabolites in urine.

Sandbaumhuter F, Aerts J, Theurillat R, Andren P, Thormann W, Jansson E Electrophoresis. 2022; 44(1-2):125-134.

PMID: 36398998 PMC: 10108174. DOI: 10.1002/elps.202200175.


Sex-dependent metabolism of ketamine and ()-hydroxynorketamine in mice and humans.

Highland J, Farmer C, Zanos P, Lovett J, Zarate Jr C, Moaddel R J Psychopharmacol. 2021; 36(2):170-182.

PMID: 34971525 PMC: 9904319. DOI: 10.1177/02698811211064922.